Sun, Apr 20, 2014, 5:54 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

BioScrip Inc. Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    bought a bunch

    by mldtextbook Mar 5, 2014 7:39 PM

    good luck with 7 it looks like about to break out above 7.50 been building a base around 7 for several weeks

  • Reply to

    bought a bunch

    by mldtextbook Mar 5, 2014 7:39 PM

    same here....just starting to position...I always buy pretty disciplined....to hard to catch the lows...I just buy on the way down after a good sell-off...once it turns and catches me...I never add position once it gets ahead of me...= catching maximum % of gain on capital....so the further it falls the larger position I'll build....patience and discipline....has worked for decades for me. GLTA

  • Reply to

    bought a bunch

    by mldtextbook Mar 5, 2014 7:39 PM

    Good luck with your position. I have a limit order for $7. This company should be much higher in a 3-5 year horizon.

    Sentiment: Strong Buy

  • Reply to

    looks like a buy

    by mgiuseff Apr 9, 2014 12:59 PM

    Zacks and most investment letters are always late to the party...they're not seeing the big picture..it is a bit of a gamble but reward may out way the risk. If this turns around they'll be upgrading after it's already made it's biggest move .

  • Reply to

    looks like a buy

    by mgiuseff Apr 9, 2014 12:59 PM

    How and why is it a buy?

  • Reply to

    looks like a buy

    by mgiuseff Apr 9, 2014 12:59 PM

    On Mar 4, 2014, Zacks Investment Research downgraded BioScrip Inc. (BIOS) to a Zacks Rank #5 (Strong Sell).

    Why the Downgrade?

    BioScrip witnessed downward estimate revisions since it reported disappointing fourth-quarter 2013 earnings results on Feb 26.

    In the fourth quarter, BioScrip’s net loss from continuing operations of 7 cents per share witnessed a massive decline from the year-ago adjusted earnings per share (EPS) of 2 cents. The results also considerably lagged the Zacks Consensus Estimate of earnings of 2 cents. Notably, the company delivered negative earnings surprises in 3 of the last 4 quarters with an average miss of 116.67%.

    BioScrip is still battling margin headwinds as the high-margin PBM business continues to decline. Although the company is working toward margin improvement, any near-term improvement is unlikely.

    Reimbursement pressure remains an overhang for the company’s home health franchise. Although Infusion Services business continues to grow at a healthy pace, the poor performance at the PBM Services segment is weighing on the margin. The dearth of any major near-term catalyst might make it difficult for BioScrip to overcome these challenges in the near future, which is also reflected in the company’s unimpressive guidance for fiscal 2014.

    According to the company, in 2014, its Infusion Services segment is expected to grow at a rate of 20% with double-digit organic growth. However, similar to this recently completed fiscal, even in 2014, growth in Infusion Services revenues will be offset by a decline in the PBM Services segment and the sale of the Home Health Services business. Total gross margin is anticipated to suffer due to the sale of Home Health, growth in the low-margin Infusion business and decline in the high-margin PBM Services segment’s gross margin.

  • Long term should be fine.

    Sentiment: Strong Buy

  • Reply to

    ballistic

    by mgiuseff Apr 8, 2014 7:47 PM

    On Mar 4, 2014, Zacks Investment Research downgraded BioScrip Inc. (BIOS) to a Zacks Rank #5 (Strong Sell).

    Why the Downgrade?

    BioScrip witnessed downward estimate revisions since it reported disappointing fourth-quarter 2013 earnings results on Feb 26.

    In the fourth quarter, BioScrip’s net loss from continuing operations of 7 cents per share witnessed a massive decline from the year-ago adjusted earnings per share (EPS) of 2 cents. The results also considerably lagged the Zacks Consensus Estimate of earnings of 2 cents. Notably, the company delivered negative earnings surprises in 3 of the last 4 quarters with an average miss of 116.67%.

    BioScrip is still battling margin headwinds as the high-margin PBM business continues to decline. Although the company is working toward margin improvement, any near-term improvement is unlikely.

    Reimbursement pressure remains an overhang for the company’s home health franchise. Although Infusion Services business continues to grow at a healthy pace, the poor performance at the PBM Services segment is weighing on the margin. The dearth of any major near-term catalyst might make it difficult for BioScrip to overcome these challenges in the near future, which is also reflected in the company’s unimpressive guidance for fiscal 2014.

    According to the company, in 2014, its Infusion Services segment is expected to grow at a rate of 20% with double-digit organic growth. However, similar to this recently completed fiscal, even in 2014, growth in Infusion Services revenues will be offset by a decline in the PBM Services segment and the sale of the Home Health Services business. Total gross margin is anticipated to suffer due to the sale of Home Health, growth in the low-margin Infusion business and decline in the high-margin PBM Services segment’s gross margin.

  • Reply to

    ballistic

    by mgiuseff Apr 8, 2014 7:47 PM

    Mentioned on CNBC as potential double, takeout candidate, turnaround story etc.

  • Tried market order, then limit, but my order never filled. What happened today?

  • On Mar 4, 2014, Zacks Investment Research downgraded BioScrip Inc. (BIOS) to a Zacks Rank #5 (Strong Sell).

    Why the Downgrade?

    BioScrip witnessed downward estimate revisions since it reported disappointing fourth-quarter 2013 earnings results on Feb 26.

    In the fourth quarter, BioScrip’s net loss from continuing operations of 7 cents per share witnessed a massive decline from the year-ago adjusted earnings per share (EPS) of 2 cents. The results also considerably lagged the Zacks Consensus Estimate of earnings of 2 cents. Notably, the company delivered negative earnings surprises in 3 of the last 4 quarters with an average miss of 116.67%.

    BioScrip is still battling margin headwinds as the high-margin PBM business continues to decline. Although the company is working toward margin improvement, any near-term improvement is unlikely.

    Reimbursement pressure remains an overhang for the company’s home health franchise. Although Infusion Services business continues to grow at a healthy pace, the poor performance at the PBM Services segment is weighing on the margin. The dearth of any major near-term catalyst might make it difficult for BioScrip to overcome these challenges in the near future, which is also reflected in the company’s unimpressive guidance for fiscal 2014.

    According to the company, in 2014, its Infusion Services segment is expected to grow at a rate of 20% with double-digit organic growth. However, similar to this recently completed fiscal, even in 2014, growth in Infusion Services revenues will be offset by a decline in the PBM Services segment and the sale of the Home Health Services business. Total gross margin is anticipated to suffer due to the sale of Home Health, growth in the low-margin Infusion business and decline in the high-margin PBM Services segment’s gross margin.

  • Turnaround story intact.

  • BioScrip, InterXion, RealD mentioned as stock picks by Oscar Schafer
    Pharmacy and home health services provider BioScrip (BIOS) was named as a stock pick and a potential takeover target by Oscar Schafer, managing partner of O.S.S. Capital Management and chairman of Rivulet Capital

    Sentiment: Strong Buy

  • Oscar Schafer, earlier on CNBC, named BIOS, INXN as stock picks

    INXN data centers in Europe...a cash cow...BIOS over 20% short

    Sentiment: Strong Buy

  • Fund manger says it's a double or triple. Turn around situation and possible take over. Second time Ive heard this mentioned. Also mentioned on Bloomberg
    a couple months ago.

  • next stop 50 day 7.75

  • its an opportunity..somehow think the window may have closed for bargain basement prices.

  • Reply to

    gabelli funds

    by chardda233 Apr 2, 2014 11:08 AM

    Interesting, took a 5.41% stake and not a passive one. Doubt they are in it to lose money.

  • Reply to

    gabelli funds

    by chardda233 Apr 2, 2014 11:08 AM

    Yes, Gabelli (GAMCO) filed a 13D on 3-31. It is interesting that they filed a 13D, indicating an activist position, and not the usual 13G, a passive investment, that most mutual funds file.

  • took a stake..i also heard another fund manager talking about a turn around and the stock could double if taken over...

BIOS
7.21-0.26(-3.48%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.